Literature DB >> 16957680

Changing rates of genetic subtypes of Prader-Willi syndrome in the UK.

Joyce E Whittington1, Jill V Butler, Anthony J Holland.   

Abstract

The genetically determined neurodevelopmental disorder, Prader-Willi syndrome (PWS), has two main genetic subtypes: a 15q11-q13 deletion affecting the paternally inherited chromosome 15 and chromosome 15 maternal uniparental disomy (mUPD) in which two maternal copies of chromosome 15 are inherited but no paternal copy. It has been accepted that these subtypes occur in approximately 70 and 25% of cases, respectively. This is the first report of a greater proportion (50%) of those with PWS due to mUPD in children presently under 5 years living in the UK. Increasing maternal age at conception is likely to explain the changing proportions in this generation of mothers.

Entities:  

Mesh:

Year:  2006        PMID: 16957680     DOI: 10.1038/sj.ejhg.5201716

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

1.  Levels of select PCB and PBDE congeners in human postmortem brain reveal possible environmental involvement in 15q11-q13 duplication autism spectrum disorder.

Authors:  Michelle M Mitchell; Rima Woods; Lai-Har Chi; Rebecca J Schmidt; Isaac N Pessah; Paul J Kostyniak; Janine M LaSalle
Journal:  Environ Mol Mutagen       Date:  2012-08-29       Impact factor: 3.216

2.  Growth hormone receptor (GHR) gene polymorphism and scoliosis in Prader-Willi syndrome.

Authors:  Merlin G Butler; Waheeda Hossain; Maaz Hassan; Ann M Manzardo
Journal:  Growth Horm IGF Res       Date:  2017-12-06       Impact factor: 2.372

3.  Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study.

Authors:  Sin T Lo; Elbrich P C Siemensma; Dederieke A M Festen; Philippe J L Collin; Anita C S Hokken-Koelega
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-12-19       Impact factor: 4.785

4.  Different distribution of the genetic subtypes of the Prader-Willi syndrome in the elderly.

Authors:  Margje Sinnema; Kees E P van Roozendaal; Marian A Maaskant; Hubert J M Smeets; John J M Engelen; Nieke Jonker-Houben; Constance T R M Schrander-Stumpel; Leopold M G Curfs
Journal:  Eur J Hum Genet       Date:  2010-05-12       Impact factor: 4.246

Review 5.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

6.  Clinical and genetic features of Prader-Willi syndrome in China.

Authors:  Wei Lu; Yan Qi; Bing Cui; Xiu-Li Chen; Bing-Bing Wu; Chao Chen; Yun Cao; Wen-Hao Zhou; Hong Xu; Fei-Hong Luo
Journal:  Eur J Pediatr       Date:  2013-08-11       Impact factor: 3.183

7.  Overrepresentation of pregnancies conceived by artificial reproductive technology in prenatally identified fetuses with Beckwith-Wiedemann syndrome.

Authors:  John P Johnson; Linda Beischel; Corbin Schwanke; Katie Styren; Amy Crunk; Jonathan Schoof; Abdallah F Elias
Journal:  J Assist Reprod Genet       Date:  2018-06-24       Impact factor: 3.412

8.  Growth Charts for Prader-Willi Syndrome During Growth Hormone Treatment.

Authors:  Merlin G Butler; Jaehoon Lee; Devin M Cox; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Elizabeth Roof; Elisabeth Dykens; Virginia Kimonis; Daniel J Driscoll
Journal:  Clin Pediatr (Phila)       Date:  2016-02-03       Impact factor: 1.168

Review 9.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

Review 10.  Apo-Ghrelin Receptor (apo-GHSR1a) Regulates Dopamine Signaling in the Brain.

Authors:  Andras Kern; Cristina Grande; Roy G Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.